The new facility will expand Merck’s Elkton site, adding small molecule manufacturing and testing capabilities, as part of a more than $70 billion U.S. investment beginning in 2025.
Join us for a high-impact roundtable where industry leaders explore how digital transformation is revolutionizing the manufacturing of new modalities—unlocking the full potential of personalized, scalable, and rapidly delivered therapies.
